Marvelon (Desogestrel, Ethinylestradiol)

The two hormones in Marvelon work together to suppress the natural surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), which stops ovulation. Ethinylestradiol stabilises the uterine lining, while desogestrel thickens cervical mucus, creating an environment that is hostile to sperm and prevents fertilisation.

The dosage regimen for Marvelon is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions should be confirmed with the prescriber.

Marvelon is intended for use only when a woman is not pregnant. If pregnancy occurs, the product should be discontinued and a healthcare provider consulted. Safety during breastfeeding has not been fully established; therefore, a prescriber should evaluate the benefits and risks before use in nursing mothers.

To order Marvelon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Marvelon contains a low‑dose estrogen (0.02 mg ethinylestradiol) combined with desogestrel, which is associated with a lower risk of androgenic side effects compared with some older progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while its side‑effect profile may be more favourable for women sensitive to weight gain or acne.

Marvelon tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Marvelon is taken orally as a single tablet each day, preferably at the same time each day. The tablets are usually packaged in a 21‑day active strip followed by a 7‑day placebo period, during which withdrawal bleeding occurs.

The most serious risks include venous thromboembolism such as deep‑vein thrombosis, pulmonary embolism, and rare arterial events like stroke or myocardial infarction. Women with a history of clotting disorders, smoking over age 35, or uncontrolled hypertension should avoid use and discuss alternatives with their clinician.

Marvelon is contraindicated in women with a known or suspected pregnancy, active or past thromboembolic disease, uncontrolled hypertension, severe liver disease, or known hypersensitivity to any component. It should also be avoided by smokers over 35 years of age and by those taking medications that markedly reduce its effectiveness.